# Phase IIb Study of IFN-K in Systemic Lupus Erythematosus

> **NCT02665364** · PHASE2 · TERMINATED · sponsor: **Neovacs** · enrollment: 185 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** IFNα-Kinoid
- **OTHER:** Placebo
- **OTHER:** ISA 51 VG

## Key facts

- **NCT ID:** NCT02665364
- **Lead sponsor:** Neovacs
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09-23
- **Primary completion:** 2018-03-15
- **Final completion:** 2020-02-04
- **Target enrollment:** 185 (ACTUAL)
- **Why stopped:** Reorganization proceedings of the sponsor
- **Last updated:** 2020-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02665364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02665364, "Phase IIb Study of IFN-K in Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02665364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*